TIDMCMI 
 
CERES MEDIA INTERNATIONAL PLC 
 
                   ("Ceres" or the "Company" or the "Group") 
 
                     Placing, update and grant of options 
 
Placing 
 
The board announces that the Company, through its broker First Columbus LLP, 
has placed 21,000,000 new ordinary shares at a price of 1 pence per share ("the 
Placing Price") raising GBP210,000 of funds before expenses ("the Placing"). 
 
The proceeds of the Placing will be used for general working capital purposes 
and to support further development of the business. 
 
The Company currently has authority to issue 10,324,556 new ordinary shares for 
cash and will therefore execute the Placing in two tranches. 
 
The first tranche of 10,000,000 new ordinary shares will occur with immediate 
effect. Application has been made to the London Stock Exchange for the 
10,000,000 new ordinary shares to be admitted to trading on AIM. Trading in 
these shares is expected to occur on or around 28 May 2012. 
 
Admission of the remaining 11,000,000 new ordinary shares will occur in a 
second tranche, subject to shareholder approval of further authorities to issue 
new ordinary shares in the Company for cash. A circular convening a general 
meeting of the Company ("the General Meeting") will shortly be posted to 
shareholders seeking, inter alia, such authority. 
 
Proposed Directors' Dealing 
 
The directors of the Company are participating in the second tranche of the 
Placing, details of each of the directors' participation in the Placing are set 
out in the table below. 
 
In addition to their participation in the Placing, the directors have agreed to 
convert certain accrued remuneration costs and unpaid expenses of GBP84,000 in to 
8,400,000 new shares in the Company at the Placing Price ("the Conversion"). 
Details of the Conversion are set out in the table below. The Conversion will 
constitute a related party transaction pursuant to the AIM Rules. Shareholders 
consent in relation to the Conversion will be sought at the General Meeting. A 
further announcement detailing the related party disclosure will be made 
subsequent to the General Meeting. 
 
Conditional on shareholder approval at the General Meeting the Company will 
issue a further 2,000,000 shares in the Company, at the Placing Price, to 
certain other creditors in lieu of balances totalling GBP20,000 ("Creditor 
Conversion"). 
 
Director        Number of     Number of    Number of     Number of         % of 
                 existing        shares   Conversion        shares     enlarged 
              shares held    subscribed       shares     following issued share 
                             for in the                Placing and     capital* 
                                Placing                 Conversion 
 
A Dowdeswell    3,527,342     2,617,000    3,000,000     9,144,342        14.9% 
 
L Barber          403,089       300,000    4,500,000     5,203,089         8.5% 
 
C Garston         379,938       283,000      900,000     1,562,938         2.5% 
 
*assuming the Placing, Conversion and Creditor Conversion occur 
 
Application for admission to trading on AIM of the second tranche of the 
Placing, the Conversion shares and the Creditor Conversion shares, totalling 
21,400,000 new ordinary shares, will occur following the General Meeting. 
 
Following the Placing, Conversion and Creditor Conversion, the so enlarged 
issued share capital of the Company will comprise 61,373,961 ordinary shares of 
1 pence each. 
 
Update 
 
The directors are encouraged by the Group's trading performance since 31 
January 2012. As announced on 30 April 2012, the directors remain cautiously 
optimistic evidenced by the gradual increase in turnover recorded to date in 
2012. Orders received in April 2012 were in excess of the total revenues for 
the 6 months to 31 January 2012. 
 
Sales of NatureWovenTM, ChorusTM and GossypTM, whilst still small by comparison 
to what the directors believe is their potential, have continued to customers 
in both the USA and Europe. Additional orders have been received for Nature 
Netting, the Company's new screening product, for high profile events taking 
place in the UK during the summer and beyond. 
 
The directors believe that the technical issues surrounding the physical fixing 
process for the Group's TierraFilmTM Window Cling product have been resolved 
and this upgraded product is expected to be available in the UK and the USA in 
June 2012. 
 
Advanced stage testing of the TierraFilmTM Backlit product continues with major 
`Out of Home' media owners and the Company anticipates approvals shortly. This 
product boasts excellent print quality combined with superior light diffusion 
characteristics compared to existing materials used. 
 
Leslie Barber, Chairman, commented: "The indications are that the Company's 
product portfolio now meets the quality, usage and price requirements of the 
marketplace and the relevant user base. Distribution gains in the USA and 
Europe are beginning to show through in sales and the response to 
NatureNettingTM and BackLit products in the UK is encouraging. The Company 
looks poised to exploit its unique compostable, recyclable and bio-degradable 
products in its core markets." 
 
Grant of options 
 
Since the Company's admission to AIM on 13 September 2011, it has agreed to 
grant options over 960,000 shares ("Admission Options") to directors and key 
senior management. The terms of the Admission Options are set out below: 
 
Vesting period: None 
 
Exercise period: Any time until 13 September 2020 
 
Exercise price: 1p 
 
Performance criteria: Company's share price in excess of 5 pence per share 
 
Directors' participation in the Admission Options is set out in the table 
below. 
 
In December 2011, the Company agreed in principal to issue further options to 
non-executive directors ("Further Options") with the objective of conserving 
cash resources. Conditional on the granting of the Further Options, the 
non-executive directors have agreed to waive the cash element of their 
remuneration and convert existing remuneration liabilities into shares in the 
Company. 
 
The terms of the Further Options are set out below: 
 
Vesting period: None 
 
Exercise period: Any time until 13 September 2020 
 
Exercise price: 1p 
 
Performance criteria: None 
 
Directors' participation in the Further Options is set out in the table below. 
 
Director       Admission          Further               Total 
                 Options          Options 
 
A Dowdeswell     500,000              nil             500,000 
 
L Barber         300,000        2,500,000           2,800,000 
 
C Garston            nil        1,000,000           1,000,000 
 
Others           160,000              nil             160,000 
 
With the exception of the options granted to C Garston, which are issued by way 
of an unapproved scheme, all other options are issued under an EMI scheme. 
 
The grant of the Admission Options and Further Options to directors is a 
related party transaction pursuant to the AIM Rules. Shareholder consent in 
relation to the grant of the Admission Options and Further Options will be 
sought at the General Meeting. A further announcement detailing the related 
party disclosure in relation to the options will be made subsequent to the 
General Meeting. 
 
For further information, please contact: 
 
Ceres Media International PLC                              Tel: 020 3178 5622 
 
Alex Dowdeswell / Leslie Barber 
 
Nominated Adviser - Cairn Financial Advisers LLP           Tel: 020 7148 7900 
 
Jo Turner / Liam Murray 
 
Broker - First Columbus LLP                                Tel: 020 3002 2070 
 
Chris Crawford / Kelly Gardiner 
 
 
 
END 
 

Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Optibiotix Health Charts.
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Optibiotix Health Charts.